For a client starting therapy with pertuzumab for metastatic breast cancer, which statement is important for the nurse to reinforce?

For a client starting therapy with pertuzumab for metastatic breast cancer, which statement is important for the nurse to reinforce?

• A. Use contraception during treatment and for 6 months afterward
• B. Stop other cancer therapies immediately
• C. Take medication on a full stomach
• D. Ignore chills during treatment

Answer: (A)

For a client starting therapy with pertuzumab for metastatic breast cancer, reinforcing the importance of using contraception during treatment and for 6 months afterward is crucial. Pertuzumab is a targeted therapy that can potentially cause harm to a developing fetus. Therefore, effective contraception is essential to prevent pregnancy while receiving this medication. This precaution ensures that any risks associated with drug exposure during pregnancy are mitigated. The recommendation to continue contraception for 6 months after treatment is based on the pharmacodynamics of pertuzumab and the potential for the drug to remain in the body for some time after discontinuation. It is vital for the nurse to emphasize this point to protect reproductive health and to inform the patient about the implications of the treatment on pregnancy. Using contraception is a standard safety protocol in oncology nursing for drugs that are known teratogens, and it prioritizes patient safety during cancer therapy. Other details regarding treatment, such as the implications of stopping other therapies, administration on an empty or full stomach, or addressing side effects like chills, are important but secondary to the critical safety measures surrounding reproductive health during cancer treatment with pertuzumab.

For a client starting therapy with pertuzumab for metastatic breast cancer, reinforcing the importance of using contraception during treatment and for 6 months afterward is crucial. Pertuzumab is a targeted therapy that can potentially cause harm to a developing fetus. Therefore, effective contraception is essential to prevent pregnancy while receiving this medication. This precaution ensures that any risks associated with drug exposure during pregnancy are mitigated.

The recommendation to continue contraception for 6 months after treatment is based on the pharmacodynamics of pertuzumab and the potential for the drug to remain in the body for some time after discontinuation. It is vital for the nurse to emphasize this point to protect reproductive health and to inform the patient about the implications of the treatment on pregnancy.

Using contraception is a standard safety protocol in oncology nursing for drugs that are known teratogens, and it prioritizes patient safety during cancer therapy. Other details regarding treatment, such as the implications of stopping other therapies, administration on an empty or full stomach, or addressing side effects like chills, are important but secondary to the critical safety measures surrounding reproductive health during cancer treatment with pertuzumab.